Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy

High risk of recurrence/progression bladder tumours is treated with Bacillus Calmette-Guérin (BCG) immunotherapy after complete resection of the tumour. Approximately 75% of these tumours express the uncommon carbohydrate antigen sialyl-Tn (Tn), a surrogate biomarker of tumour aggressiveness. Such c...

Full description

Bibliographic Details
Main Author: Lima, Luís (author)
Other Authors: Severino, Paulo (author), Silva, Mariana (author), Miranda, Andreia (author), Tavares, Ana (author), Pereira, Sofia (author), Fernandes, Elisabete (author), Cruz, Ricardo (author), Amaro, Teresina (author), Reis, Celso (author), Dall'Olio, Fabio (author), Amado, Francisco (author), Videira, Paula (author), Santos, Lúcio (author), Ferreira, José Alexandre (author)
Format: article
Language:eng
Published: 2013
Subjects:
Bacillus Calmette-Guerin
BCG immunotherapy
Bladder Cancer
Sialyl-Tn
Sialyl-6-T
Tumor glycosylation
Online Access:http://hdl.handle.net/10400.22/3171
Country:Portugal
Oai:oai:recipp.ipp.pt:10400.22/3171

Internet

http://hdl.handle.net/10400.22/3171

Similar Items